Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Broadwood Capital Trims Its Stake in Questcor Pharmaceuticals Inc (QCOR)

Neal C. Bradsher‘s Broadwood Capital has trimmed its stake in Questcor Pharmaceuticals Inc (NASDAQ:QCOR) by selling 20,000 shares. According to the filing with the SEC, Broadwood disposed the securities in one deal at a price of $65 per share. Following the transaction, the fund still owns around 2.78 million shares. The stake currently amasses around 4.5% of the company’s stock.

Questcor Pharmaceuticals Inc (NASDAQ:QCOR)

Overall, Broadwood Capital reduced significantly its position in biopharmaceutical company Questcor Pharmaceuticals Inc (NASDAQ:QCOR). In its latest 13F, the fund revealed holding almost 3.3 million shares of the company. Palo Alto Investors, led by William Leland Edwards, is another investor with a $38.05 million stake, which contains around 656,000 shares of the company. Christopher R. Hansen’s Valiant Capital disclosed holding 531,600 shares in its latest 13F.

Questcor Pharmaceuticals Inc (NASDAQ:QCOR)’s stock returned almost 30% over the past six months, trailing a P/E of 14.8x. A couple of days ago, the company paid a quarterly dividend of $0.30 per share. Last month, Questcor Pharmaceuticals Inc (NASDAQ:QCOR) announced that it has repurchased around 500,000 shares of its common stock at an average price of $57.21 apiece.

Broadwood Capital is a mid-sized New York City-based fund with an equity portfolio worth around $468.5 million. At the beginning of the month, the fund disclosed raising its stake in BioTime, Inc. (NYSEMKT:BTX) to 9.52 million shares, from some 9.02 million held previosly. Overall, the stake currently amasses 14.1% of BioTime’s outstanding stock.

Among the largest stakes revealed by Broadwood in its latest 13F, is STAAR Surgical Company (NASDAQ:STAA), in which the fund holds a $86.68 million stake, which amasses 6.4 million shares. Another one is Monster Beverage Corp (NASDAQ:MNST), in which Broadwood owns 1.61 million shares, worth $84.08 million.

Disclosure: none

Recommended Reading:

Hedge Fund News: Rob Citrone, David Tepper & Paul Singer

Hedge Fund Highlights: Steven Cohen, Barry Rosenstein & George Soros

Corvex Capital Is Going Long Signet Jewelers Ltd. (SIG)

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!